The current National Comprehensive Cancer Network (NCCN) guidelines recommend allogeneic HCT solely for fit patients with relapsed/refractory CLL after prior treatment with both a BTK and BCL2 inhibitor (22). This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.